Cingulate cortex

Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Retrieved on: 
Wednesday, January 4, 2023
Precision Time Protocol Industry Profile, PTR, Migraine, Anxiety, Xerostomia, Food, Bipolar disorder, Child, Insomnia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Depression, Adolescence, Behavioral medicine, ALS, Patient, Hypothyroidism, ADHD, Safety, Cingulate cortex, FDA, Attention deficit hyperactivity disorder predominantly inattentive, Conference, Psychiatry, Pharmaceutical industry

KANSAS CITY, Kan., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the initiation of the first Phase 3 clinical trial of its lead candidate CTx-1301, a novel, investigational, trimodal, extended release tablet formulation of dexmethylphenidate, a compound approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD).

Key Points: 
  • The meetings will take place at the same time as the annual J.P. Morgan Healthcare Conference.
  • The Phase 3 clinical trial is an adult dose-optimization study to assess the onset and duration of efficacy along with the safety of CTx-1301 in adults with ADHD compared to placebo.
  • “Physicians have been wanting a treatment that provides entire active-day efficacy to treat ADHD.
  • Cingulate is available to partner with existing therapeutic providers in these and other categories to improve delivery and provide ideal, once-daily dosing solutions for patients.

Cingulate Benzinga All Live Access Appearance Rescheduled for December 16

Retrieved on: 
Thursday, December 1, 2022
Anxiety, PTR, Attention, ADHD, Precision Time Protocol, Patient, Attention deficit hyperactivity disorder, CST, Doctor of Pharmacy, Cingulate cortex, Pharmaceutical industry

The appearance had previously been scheduled for Friday December 2, 2022, at 10:00 a.m. CST.

Key Points: 
  • The appearance had previously been scheduled for Friday December 2, 2022, at 10:00 a.m. CST.
  • The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulates PTR platform into the anxiety therapeutic area.
  • The event may be viewed live on Benzingas YouTube channel, Benzinga All Access , and will also be available for viewing on Cingulates website at cingulate.com/investors .
  • Cingulate is headquartered in Kansas City.

Cingulate to Participate in Benzinga All Live Access Event

Retrieved on: 
Wednesday, November 30, 2022
Anxiety, PTR, Attention, ADHD, Precision Time Protocol, Patient, Attention deficit hyperactivity disorder, CST, Cingulate cortex, Pharmaceutical industry

KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday December 2, 2022, at 10 a.m. CST.

Key Points: 
  • KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday December 2, 2022, at 10 a.m. CST.
  • The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulates PTR platform into the anxiety therapeutic area.
  • The event may be viewed live on Benzingas YouTube channel, Benzinga All Access , and will also be available for viewing on Cingulates website at cingulate.com/investors .
  • Cingulate is headquartered in Kansas City.

Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Monday, November 14, 2022
Adolescence, GA, Tablet, CDMO, Safety, Federal Food, Drug, and Cosmetic Act, Security (finance), Master service agreement, Cingulate cortex, Research and development, R, Administration, Anxiety, Table, New Drug Application, Attention, Pharmacokinetics, Buspirone, G&A, Solubility, NDA, Research, Nature, Drug discovery, Society, Dextroamphetamine, Attention deficit hyperactivity disorder, Science, Pharmacology, Drug Quality and Security Act, PTR, IND, DEA, Annual report, MSA, ADHD, Gastrointestinal tract, Precision Time Protocol Industry Profile, Patient, Pharmaceutical industry, Generic drug, Vaccine

KANSAS CITY, Kan., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update. Highlights include a newly executed Master Services Agreement (MSA) and multiple clinical program updates on its lead Attention Deficit / Hyperactivity Disorder (ADHD) candidate, CTx-1301 (dexmethylphenidate), as well as anxiety asset CTx-2103 (buspirone HCl).

Key Points: 
  • Societal CDMO will dedicate a specific manufacturing suite within its Gainesville, GA facility and outfit it with proprietary equipment owned by Cingulate.
  • CTx-1301: Cingulate advanced its clinical program for CTx-1301 on the expedited approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
  • CTx-2103: Cingulate is constructing a clinical program for CTx-2103 toward an expedited approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
  • In addition, manufacturing of the Phase 3 clinical supply for the fixed-dose study began in the first quarter of 2022 with continued activity through the third quarter of 2022.

Cingulate Inc. to Present at Investor Summit Group's Q4 Conference

Retrieved on: 
Thursday, November 3, 2022
Cingulate cortex, Sheraton New York Times Square Hotel, Complimentary, ADHD, Precision Time Protocol, Seventh Avenue, CEO, Anxiety, IR, NASDAQ, Technology, Patient

Management will be available for investor meetings throughout the day.

Key Points: 
  • Management will be available for investor meetings throughout the day.
  • ET
    Location: Sheraton New York Times Square Hotel, 811 7th Avenue, W 53rd St, New York, NY 10019
    The conference is completely complementary to qualified investors.
  • With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
  • Cingulate is headquartered in Kansas City.

Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update

Retrieved on: 
Monday, October 24, 2022
Physician, U.S. Securities and Exchange Commission, API, Drug Quality and Security Act, Therapy, SEC, Master service agreement, Prevalence, IND, Norepinephrine, New Drug Application, Attention, NDA, GA, Food and Drug Administration Amendments Act of 2007, DEA, NASDAQ, ADHD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MSA, Patient, Adult, Annual report, NASD, Cingulate cortex, Security (finance), Attention deficit hyperactivity disorder, Science, Securities Act of 1933, Technology, Food, Adolescence, Precision Time Protocol, Society, Behavior, CDMO, Health, Securities Exchange Act of 1934, Safety, Ageing, Nature, Anxiety, GLOBE, Brain, Child, FDA, Learning disability, Solution, Fine chemical, Pharmaceutical industry, Drug discovery, MD

Societal CDMO will dedicate a specific manufacturing suite within its Gainesville, GA facility and outfit it with proprietary equipment supplied by Cingulate.

Key Points: 
  • Societal CDMO will dedicate a specific manufacturing suite within its Gainesville, GA facility and outfit it with proprietary equipment supplied by Cingulate.
  • The work that we will conduct under this MSA with Cingulate provides an excellent opportunity for Societal CDMO to showcase our teams extensive expertise in formulating and manufacturing complex therapeutics to assist in the delivery of innovative drugs to the patients that need them.
  • We are pleased that Cingulate has trusted Societal CDMO to carry out these essential activities to support CTx-1301 at such a critical juncture on its path through clinical development and toward commercialization.
  • With an expertise in solving complex manufacturing problems, Societal CDMO is a leading CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market.

Cingulate to Present at LD Micro Investor Conference

Retrieved on: 
Thursday, October 20, 2022
Anxiety, NASDAQ, Patient, Cingulate cortex, Lists of diseases, Technology, Security (finance), Pharmaceutical industry

To arrange a meeting with Cingulate, please contact your conference representative.

Key Points: 
  • To arrange a meeting with Cingulate, please contact your conference representative.
  • Investors may also contact Cingulate investor relations at [email protected] to arrange an in-person meeting.
  • With an initial focus on the treatment of neurological disorders, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
  • Cingulate is headquartered in Kansas City.

Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103

Retrieved on: 
Monday, September 19, 2022
People, Securities Exchange Act of 1934, Half-life, Tablet, Gastrointestinal tract, Safety, Precision Time Protocol, Lists of diseases, COVID-19, Risk, Gallup's List of Most Widely Admired People of the 20th Century, EBL, Cingulate cortex, Drug Quality and Security Act, Nature, Company, Nuclear medicine, Securities Act of 1933, ADHD, Anxiety disorder, U.S. Securities and Exchange Commission, Patient, Mental health, Potential, CEO, Technology, Benzodiazepine, Disorder, Barbiturate, Annual report, Anxiety, Diagnosis, NASDAQ, Solubility, Security (finance), Pharmacokinetics, GLOBE, SEC, Congress, Fear, Screen for child anxiety related disorders, Pharmaceutical industry, Generic drug, Medicine, Buspirone

KANSAS CITY, Kan., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced findings from its formulation study for CTx-2103, the Company’s asset for the management of anxiety-related disorders. The data was featured in a poster presentation at the 2022 Psych Congress meeting, taking place September 17-20 in New Orleans, LA.

Key Points: 
  • The data was featured in a poster presentation at the 2022 Psych Congress meeting, taking place September 17-20 in New Orleans, LA.
  • The readout of the data is a crucial step in our quest to bring the best-possible, once-daily formulation of buspirone to patients, said ShaneJ.
  • In the study, the pharmacokinetics were evaluated for three multi-layered, timed-release oral tablets and one immediate release dose of buspirone.
  • Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using the Companys innovative PTR drug delivery platform technology.

Cingulate to Participate in Benzinga All Live Access Event

Retrieved on: 
Monday, August 15, 2022
ADHD, CST, GLOBE, Technology, Attention deficit hyperactivity disorder, Patient, PTR, Attention, Anxiety, NASDAQ, Cingulate cortex, Precision Time Protocol, Public relations, Pharmaceutical industry

KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on August 19, 2022, at 9 a.m. CST.

Key Points: 
  • KANSAS CITY, Kan., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on August 19, 2022, at 9 a.m. CST.
  • The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulates PTR platform into the anxiety therapeutic area.
  • The event may be viewed live on Benzingas YouTube channel, Benzinga All Access , and will also be available for viewing on Cingulates website at cingulate.com/investors .
  • For more information visit Cingulate.com
    Head of Investor & Public Relations, Cingulate

Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year

Retrieved on: 
Monday, July 25, 2022
Kansas City Southern, Shell Oil Company, CFO, GLOBE, PricewaterhouseCoopers, Anxiety, Service, Industry, U.S. Securities and Exchange Commission, CEO, NYSE, SEC, CFOS, Securities Act of 1933, Securities Exchange Act of 1934, City, Nature, NASDAQ, Organization, Precision Time Protocol, Work, Sheraton Kansas City Hotel at Crown Center, Technology, American City Business Journals, ADHD, Security (finance), Patient, Annual report, Cingulate cortex, LLC, In-store financial services, Financial management, Comptroller, Management, Mobile phone operator, Nasdaq

Lou was among 16 CFOs representing the best in financial management and have proven themselves invaluable to their companies and organizations.

Key Points: 
  • Lou was among 16 CFOs representing the best in financial management and have proven themselves invaluable to their companies and organizations.
  • A panel of independent judges selected this years honorees who were celebrated at a special ceremony July 22 at the Loews Kansas City Hotel.
  • Prior to this, Lou was Vice President & Comptroller for Kansas City Southern, a NYSE company, for 16 years.
  • Lou has extensive corporate and not-for-profit board experience and was also recognized by the Kansas City Business Journal as CFO of the Year in 2012.